We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SCLP Scancell Holdings Plc

0.00 (0.0%)
01 Dec 2023 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Scancell Holdings Plc LSE:SCLP London Ordinary Share GB00B63D3314 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 10.975 10.50 12.00 - 0.00 07:40:43
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 5.27M -11.94M -0.0146 -7.51 89.78M

Scancell Share Discussion Threads

Showing 62376 to 62398 of 65275 messages
Chat Pages: Latest  2503  2502  2501  2500  2499  2498  2497  2496  2495  2494  2493  2492  Older
The market does not understand the situation.

Remember the rest of the pipeline is looking good and Moditope looks like it will be a viable treatment also. We have only started full dose Modi-1 with CPI.

Additionally, Scancell has recruited a fourth cohort of three patients receiving full dose Modi-1 in combination with the checkpoint inhibitor nivolumab. Subject to a safety committee review meeting scheduled to take place in August, this cohort will be expanded to 21 patients in both head and neck and renal cancer. Preliminary topline data from these cohorts is expected to be reported in 2024.


Yes....unfortunately you aren't buying drugs that work on cancer for less than are buying a stock ticker.
You need to get that totally straight in your mind !!
Stock tickers are not injected.
They are traded by peeps solely intent on making a profit or rationalising a loss.
Stake bulls will be flushed.
Stocks follow patterns....they don't follow science !

Global Incidence of Ovarian Cancer in 2020. In 2020, a total of 313,959 new cases of ovarian cancer were recorded globally, with an ASR incidence of 6.6 per 100,000

Worldwide, an estimated 431,288 people were diagnosed with kidney cancer in 2020

Worldwide, an estimated 562,328 people were diagnosed with head and neck cancer in 2020

If Modi-1 improves on current treatments it will be very valuable.

Ivyspivey / ruck... I'm afraid ivspivey purchasing shares at 22p during a "hype" period as he describes it - and then trumpeting it here - does not showcase admirable restraint. But your posts do showcase the level of total horsesh1t you will both spout to avoid accepting the bleedin' obvious... ATB
but i had already bought over 300,000 loz between 8p and 12p on the way up ....

have you calculated that ?


anyway took profits ... then and the

last profit take was £30,000 ... built a carpark

now fully rented yielding its cost per annum

you really need to control your emotions Loz

Rattled -
"Lozan has made Nothing ......... !!"
REALITY = 55,500 shares at 46p+ = COST £25,000
.. NOW worth cira £7,000
You bet THEY are

the real lozan
Ivy ... sorry i can't quote you my losers i am still ahead


heat damage at 20.5 c


Nana sold the house so paid the debt so no matter to me unlike the huge numbers of people suffering financial pain due to your Govt complete incompetence in handling the economy.
You always quote the losers and never the winners lol but you missed out SCLP as we know your only share and we know how badly that is performing

So those that went to the AGM stated that Lindy had to hold back her excitement as it was too early but she would shout it from the rooftops at the right time. Well that was 9 months ago, so now it is not too early, reality has kicked in and she has nothing to shout from the rooftops. She is like a footballer who is the best player in training, looks world class, unbelievable skills but when the big match comes around , floodlights on, full stadium, TV cameras, surrounded by genuine world class players and she doesn't live up to expectations. I told you for over a year Covidity would go nowhere and was shouted down, the Chickens are coming home.
Absolutely Plasbryn no one is saying it is easy and LD is a magnificent Scientist and am sure very caring and wants to battle cancer as hard as she can.
I also believe as an expert and not prone to hype that when she does seem excited it is a real significant event.
As it is so difficult for us mere mortals to fully digest the significance of Mondays news the words and demeanour of those that do is of interest well to me anyway.
I was disappointed like some and others thought she was fine well as I said we all make our own judgement calls based on our own interpretations.

Rattled ?

i would be rattled if i held subprime interest only debt Ivy ..........

But with Irons in the Fire ... Scancell is not rattling the tin yet

and your own predictions with HVO MTFB FRR have not turned out well for you so don't get to carried away

Lozan has made Nothing ......... !!

Clutching at straws -
"Health Warning
above 40c "
REALITY = 20.5 C at 8.30 AM local time
REALITY = Folks are well AWARE of 'The BUY,BUY,BUY and HOLD ' SCAM boys CLUB
REALITY = GREED is the BAIT on which the TRAP attracts it's victims.....The ONLY way OUT of the TRAP is to attract more "NO RISK here,,,We are MINTED" 'victims'

the real lozan
It must be tough for LD and everyone in this science. It's not like designing a widget. This product has deep emotional aspects for all involved. Now the trials are live the teams are dealing with the all the implications which i can only imagine is hard at times. There is of course no magic cure for everything and to do interviews balancing excitement with respect must be so difficult. LD is a deeping caring women and i admire her 100%. Hope this post makes sense.
Morning Ivy, Yes, some people think "restraint" is synonymous with "not investing". In fact, it is possible to invest and show restraint. Price paid, timing and level of commitment are all areas where restraint can be applied, also selling a few when the price peaks.
Morning as you say Ruck it was a general warning to patiently wait for news and not to go in deep based on the conviction of self appointed experts which over the years here have proved false flags.
You can of course based on individual trading styles or combination of there of buy or sell based on sentiment and TA.
I keep it simple I buy when I expect the price to go up- it may be short or long term and I might get it right or get it wrong as none of us can predict with certainty as some claim.
So if I bought at 22p at a time of “euphoria̶1; based on retail sentiment then I would generally position size and be in for a short term momentum play.It bears no relation to going all in expecting £6-8 a share based on listening to anonymous BB posters and then as being disappointed.
I am surprised that WW a self proclaimed very experienced investor who has sat through loads of investor presentations appears to comment like a complete novice.
I thought the LD talk was low key especially given the anticipated hype and that us my judgement call whilst others have taken a different view.
The only reaction that matters is the market reaction and the likes of a Lozan have called that much better than likes of Nana.
I take no pleasure in that as it means that Modi has not fully delivered for the trial patients and yes there were some encouraging signs but like Bermuda who most people respect as a great judge of informed and balanced opinion my general feeling was of disappointment and that feeling I though echoed by LD performance.
Others can disagree which is fine that is what the boards are for but judging by the response from likes of Nana and WW etc they do seem very rattled.
Bit like buying a SARF London flat at £500k looks on the surface like a foolish move but if you sell it for £1m then it is a smart move but if it follows the trajectory of the SCLP share price then it will turn out to be a bad move.
So perhaps you might be better off listening to advice of others and consider things like Elliot Waves as having an open mind may just improve your decision making ability.

it is looking very much like SCIB1 is tipping the balance in solid cancer with 2 checkpoint support with Lindy looking very confident with this approach, don't forget SCIB1 started with just one check point and approval of ctl4 combo drove the addition
if Lag3 helps ... which it does, you may even see that included in a further cohort probably using ISCIB

Tick tock we will get there

A phase II/III, RELATIVITY-047, global, double-blind, randomised study evaluated dual inhibition of LAG-3 and PD-1 using a new combination of LAG-3–blocking antibody relatlimab and PD-1–blocking antibody nivolumab, as compared with nivolumab alone. Blinded independent assessment of the primary endpoint showed that progression-free survival (PFS) was longer with relatlimab–nivolumab combination than with single agent nivolumab.

The separation of the PFS curves occurred at the initial postbaseline assessment at approximately 12 weeks and was sustained thereafter. Relatlimab–nivolumab also had the PFS benefit over nivolumab in prespecified subgroups. Relatlimab-nivolumab combination showed no new safety signals. RELATIVITY-047 investigators led by Dr. Hussein A. Tawbi of the Department of Melanoma Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center in Houston, TX, US published their findings in the 6th January 2022 issue of The New England Journal of Medicine.

LAG-3 is a cell-surface molecule that is expressed on immune cells, including T cells, and negatively regulates T-cell proliferation and effector T-cell function. It is upregulated in many tumour types, including melanoma. LAG-3 and PD-1 are distinct inhibitory immune checkpoints that are often co-expressed on tumour-infiltrating lymphocytes. In preclinical models, dual inhibition of LAG-3 and PD-1 showed synergistic antitumour activity.

Relatlimab is a first-in-class antibody that binds to LAG-3 and restores the effector function of exhausted T cells. In a phase I/II dose-escalation and cohort-expansion study, the combination of relatlimab and nivolumab showed antitumour activity, including durable objective responses in patients with melanoma that relapsed after, or was refractory to, PD-1 inhibition.

In RELATIVITY-047, the study team evaluated relatlimab and nivolumab as a fixed-dose combination as compared with nivolumab alone when administered intravenously every 4 weeks to patients with previously untreated metastatic or unresectable melanoma.

The median PFS was 10.1 months (95% confidence interval [CI] 6.4 to 15.7) with relatlimab–nivolumab as compared with 4.6 months (95% CI 3.4 to 5.6) with nivolumab (hazard ratio for progression or death 0.75, 95% CI 0.62 to 0.92; p = 0.006 by the log-rank test). Progression-free survival at 12 months was 47.7% (95% CI 41.8 to 53.2) with relatlimab–nivolumab as compared with 36.0% (95% CI 30.5 to 41.6) with nivolumab.

If you have the T cells ....... you can work with them

if you don't you can't

Modi1 induces the T cells

so now Scancell has to work out the best way to enhance the response ....

its about "Tipping the balance"

Lymphocyte-activated gene 3 (LAG-3) is a cell surface inhibitory receptor and a key regulator of immune homeostasis with multiple biological activities related to T-cell functions. LAG-3 is considered a next-generation immune checkpoint of clinical importance, right next to programmed cell death protein 1 (PD-1) and cytotoxic T-cell lymphocyte antigen-4 (CTLA-4). Indeed, it is the third inhibitory receptor to be exploited in human anticancer immunotherapies. Several LAG-3-antagonistic immunotherapies are being evaluated at various stages of preclinical and clinical development.

""""""In addition, combination therapies blocking LAG-3 together with other immune checkpoints are also being evaluated at preclinical and clinical levels. Indeed, the co-blockade of LAG-3 with PD-1 is demonstrating encouraging results. A new generation of bispecific PD-1/LAG-3-blocking agents have also shown strong capacities to specifically target PD-1+ LAG-3+ highly dysfunctional T cells and enhance their proliferation and effector activities.""""""

Here we identify and classify preclinical and clinical trials conducted involving LAG-3 as a target through an extensive bibliographic research. The current understanding of LAG-3 clinical applications is summarized, and most of the publically available data up to date regarding LAG-3-targeted therapy preclinical and clinical research and development are reviewed and discussed.

Health Warning


above 40c

if you click the link it has a lovely picture showing the effect
you see trials are designed so that we understand ... but others are also researching

so lets look at a cancer that the CD8 has no target ......... lost MHC1

but the cancer still has MHC 11 ... so the CD4 is still active

so it may mean another cohort to find the sweet spot ............

by adding a lag 3 component ...... so DO MOT SAY modi1 does not work

it does ............... what Lindy will be doing is working out how can we make it better !!

the stockmarket full of Knowlesi go into fail mode ! why .. "not thinking enough"

and SCIB1 is still the bed rock !!

Classic Hodgkin lymphoma (cHL) responds markedly to PD-1 blockade therapy, and the clinical responses are reportedly dependent on expression of major histocompatibility complex class II (MHC-II). This dependence is different from other solid tumors, in which the MHC class I (MHC-I)/CD8+ T-cell axis plays a critical role. In this study, we investigated the role of the MHC-II/CD4+ T-cell axis in the antitumor effect of PD-1 blockade on cHL. In cHL, MHC-I expression was frequently lost, but MHC-II expression was maintained. CD4+ T cells highly infiltrated the tumor microenvironment of MHC-II–expressing cHL, regardless of MHC-I expression status. Consequently, CD4+ T-cell, but not CD8+ T-cell, infiltration was a good prognostic factor in cHL, and PD-1 blockade showed antitumor efficacy against MHC-II–expressing cHL associated with CD4+ T-cell infiltration. Murine lymphoma and solid tumor models revealed the critical role of antitumor effects mediated by CD4+ T cells: an anti-PD-1 monoclonal antibody exerted antitumor effects on MHC-I−MHC-II+ tumors but not on MHC-I−MHC-II− tumors, in a cytotoxic CD4+ T-cell–dependent manner. Furthermore, LAG-3, which reportedly binds to MHC-II, was highly expressed by tumor-infiltrating CD4+ T cells in MHC-II–expressing tumors. Therefore, the combination of LAG-3 blockade with PD-1 blockade showed a far stronger antitumor immunity compared with either treatment alone. We propose that PD-1 blockade therapies have antitumor effects on MHC-II–expressing tumors such as cHL that are mediated by cytotoxic CD4+ T cells and that LAG-3 could be a candidate for combination therapy with PD-1 blockade.

knowlesi ... its not Modi1 that is doing anything ...

Its the CD4 T cells activated by Modi1 ... and they are working

and doing more than any other treatment ...........

you seem to have missed that !

the question is can we make them work better

plenty of irons in the fire .. we also have a T cell booster

Chat Pages: Latest  2503  2502  2501  2500  2499  2498  2497  2496  2495  2494  2493  2492  Older

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |